Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.595 USD | -0.31% | -1.54% | +13.12% |
Mar. 15 | RBC Cuts Price Target on aTyr Pharma to $16 From $19, Keeps Outperform Rating, Speculative Risk Qualifier | MT |
Mar. 14 | Transcript : ATyr Pharma, Inc., Q4 2023 Earnings Call, Mar 14, 2024 |
Financials (USD)
Sales 2024 * | 2.62M | Sales 2025 * | 9.26M | Capitalization | 109M |
---|---|---|---|---|---|
Net income 2024 * | -63M | Net income 2025 * | -66M | EV / Sales 2024 * | 41.4 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 11.7 x |
P/E ratio 2024 * |
-1.61
x | P/E ratio 2025 * |
-1.67
x | Employees | 58 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.38% |
Latest transcript on aTyr Pharma, Inc.
1 day | -0.31% | ||
1 week | -1.54% | ||
Current month | -18.21% | ||
1 month | -16.93% | ||
3 months | +2.90% | ||
6 months | +28.63% | ||
Current year | +13.12% |
Managers | Title | Age | Since |
---|---|---|---|
Sanjay Shukla
CEO | Chief Executive Officer | 52 | 16-03-29 |
Jill Broadfoot
DFI | Director of Finance/CFO | 63 | 18-07-29 |
Lisa Carey
CTO | Chief Tech/Sci/R&D Officer | - | 15-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Schimmel
FOU | Founder | 83 | 05-09-07 |
Tim Coughlin
CHM | Chairman | 57 | 17-04-09 |
John K. Clarke
BRD | Director/Board Member | 70 | 05-08-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 1.595 | -0.31% | 306,540 |
24-04-24 | 1.6 | -1.23% | 288,059 |
24-04-23 | 1.62 | -1.22% | 238,347 |
24-04-22 | 1.64 | +2.50% | 293,599 |
24-04-19 | 1.6 | -1.23% | 159,073 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.12% | 109M | |
+1.12% | 43.84B | |
+6.77% | 41.68B | |
+45.26% | 41.25B | |
-11.96% | 27.04B | |
+6.01% | 25.53B | |
-24.92% | 18.18B | |
-3.63% | 12.29B | |
+27.16% | 12.29B | |
+7.30% | 11.15B |
- Stock Market
- Equities
- LIFE Stock